- Home
- PLRZ vs LIPO Comparison
PLRZ vs LIPO Comparison
Compare PLRZ & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRZ
- LIPO
- Stock Information
- Founded
- PLRZ 2005
- LIPO 2005
- Country
- PLRZ Israel
- LIPO United States
- Employees
- PLRZ N/A
- LIPO N/A
- Industry
- PLRZ
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- PLRZ
- LIPO Health Care
- Exchange
- PLRZ NYSE
- LIPO Nasdaq
- Market Cap
- PLRZ 3.4M
- LIPO 3.5M
- IPO Year
- PLRZ 2024
- LIPO 2022
- Fundamental
- Price
- PLRZ $3.29
- LIPO $2.66
- Analyst Decision
- PLRZ
- LIPO Strong Buy
- Analyst Count
- PLRZ 0
- LIPO 1
- Target Price
- PLRZ N/A
- LIPO $16.00
- AVG Volume (30 Days)
- PLRZ 7.1M
- LIPO 169.2K
- Earning Date
- PLRZ 02-15-2025
- LIPO 11-14-2024
- Dividend Yield
- PLRZ N/A
- LIPO N/A
- EPS Growth
- PLRZ N/A
- LIPO N/A
- EPS
- PLRZ N/A
- LIPO N/A
- Revenue
- PLRZ N/A
- LIPO $483,533.00
- Revenue This Year
- PLRZ N/A
- LIPO N/A
- Revenue Next Year
- PLRZ N/A
- LIPO N/A
- P/E Ratio
- PLRZ N/A
- LIPO N/A
- Revenue Growth
- PLRZ N/A
- LIPO 0.78
- 52 Week Low
- PLRZ $0.77
- LIPO $2.21
- 52 Week High
- PLRZ $4.80
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- PLRZ N/A
- LIPO 45.43
- Support Level
- PLRZ N/A
- LIPO $2.53
- Resistance Level
- PLRZ N/A
- LIPO $2.79
- Average True Range (ATR)
- PLRZ 0.00
- LIPO 0.29
- MACD
- PLRZ 0.00
- LIPO -0.01
- Stochastic Oscillator
- PLRZ 0.00
- LIPO 12.62
About PLRZ POLYRIZON LTD
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.